Volume: 56 Issue: 1
Year: 2025, Page: 162-169, Doi: https://doi.org/10.51966/jvas.2025.56.1.162-169
Received: Oct. 1, 2024 Accepted: Dec. 3, 2024 Published: March 31, 2025
Metastasis-associated protein 1 (MTA1), a key component of the nucleosome remodelling and histone deacetylase (NuRD) complex promotes cancer progression by regulating key pathways involved in oncogenesis, angiogenesis, metastasis and apoptosis. This study examined the immunohistochemical (IHC) expression of MTA1 in comparison to histological subtype, grade and hormone receptor expression in malignant canine mammary tumours (CMTs). Histopathological analysis confirmed that all tumours were malignant and carcinosarcoma was identified as the most prevalent subtype. All tumours showed moderate to strong MTA1 expression, of which four cases showed negative estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) immunostaining and were identified as triple-negative breast cancers (TNBCs). Two cases each of HER2-positive subtype and luminal tumours with HER2-positivity were identified. One case each of luminal tumour with ER negativity and PR negativity was identified. This preliminary investigation on MTA1 expression in CMTs shed light on hormone receptor signalling and MTA 1 in the pathogenesis and the molecular mechanisms involved in the disease, potentially benefiting both canine and human patients.
Keywords: Metastasis-associated protein 1, triple-negative breast cancer, Estrogen receptor, progesterone receptor, Human epidermal growth factor receptor 2
Augsburger, D., Nelson, P.J., Kalinski, T., Udelnow, A., Knösel, T., Hofstetter, M., Qin, J.W., Wang, Y., Gupta, A.S., Bonifatius, S. and Li, M. 2017. Current diagnostics and treatment of fibrosarcoma–perspectives for future therapeutic targets and strategies. Oncotarget. 8: 104638
Cheng, C.W., Liu, Y.F., Yu, J.C., Wang, H.W., Ding, S.L., Hsiung, C.N., Hsu, H.M., Shieh, J.C., Wu, P.E. and Shen, C.Y. 2012. Prognostic significance of cyclin D1, β-catenin and MTA1 in patients with invasive ductal carcinoma of the breast. Ann. Surg. Oncol. 19: 4129-4139.
Clemente, M., Perez-Alenza, M.D., Illera, J.C. and Peña, L. 2010. Histological, immunohistological and ultrastructural description of vasculogenic mimicry in canine mammary cancer. Vet. Pathol. 47: .265-274.
Christy, M.J., Sajitha, I. S., Devi, S. S., Dhanush, K. B. and Sudheesh, S. N. 2022. Study on histopathological subtypes and grading of canine mammary tumours. J. Vet. Anim. Sci. 53: 85-88
Geraldes, M., Gärtner, F. and Schmitt, F. 2000. Immunohistochemical study of hormonal receptors and cell proliferation in normal canine mammary glands and spontaneous mammary tumours. Vet. Record. 146: 403-406.
Goldschmidt, M., Peña, L., Rasotto, R. and Zappulli, V. 2011. Classification and grading of canine mammary tumours. Vet. Pathol. 48: 117-131.
Huber, D., Hatzipanagiotou, M., Schüler-Toprak, S., Ortmann, O. and Treeck, O. 2024. Effects of Endocrine Interventions Targeting ERα or PR on Breast Cancer Risk in the General Population and Carriers of BRCA1/2 Pathogenic Variants. Int. J. Mol. Sci.25: 5894.
Iqbal, N. and Iqbal, N. 2014. Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Mol. Biol. Int. 2014: 852748.
Jang, K.S., Paik, S.S., Chung, H., Oh, Y.H. and Kong, G. 2006. MTA1 overexpression correlates significantly with tumour grade and angiogenesis in human breast cancers. Cancer Sci. 97: 374-379.
Lanning, N.J., Castle, J.P., Singh, S.J., Leon, A.N., Tovar, E.A., Sanghera, A., MacKeigan, J.P., Filipp, F.V. and Graveel, C.R. Metabolic profiling of triple-negative breast cancer cells reveals metabolic vulnerabilities. Cancer Metab. 5: 1-14.
Manavathi, B., Singh, K. and Kumar R. 2007. MTA family of coregulators in nuclear receptor biology and pathology. Nucl.recept. signal. 5. Available: https://doi.org/10.1621/nrs.05010.
Martin, M.D., Hilsenbeck, S.G., Mohsin, S.K., Hopp, T.A., Clark, G.M., Osborne, C.K., Allred, D.C. and O’Connell, P. 2006. Breast tumours that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapies. Breast Cancer Res. Treat. 95: 7-12.
Mathew, R., Sajitha, I.S., Nair, S.S., Krishna, B.D. and Abraham, M.J. 2019. Canine mammary tumours: Histological malignancy grading as a prognostic indicator. Pharm. Innov. 8: 149-151.
Niyas N., Sajitha I.S., Prasanna K.S., Devi S.S., Nair S.S., Anseena A.K. and Afsal S. 2024. Histopathological and immunophenotypical classification of canine mammary tumours. J. Vet. Anim. Sci. 55: 122-128
Nagaraj, S.R.M., Shilpa, P., Rachaiah, K. and Salimath, B.P. 2015. Crosstalk between VEGF and MTA1 signalling pathways contribute to aggressiveness of breast carcinoma. Mol. Carcinog. 54: 333-350.
Orrantia-Borunda, E., Anchondo-Nuñez, P., Acuña-Aguilar, L.E., Gómez-Valles, F.O. and Ramírez-Valdespino, C.A. 2022. Subtypes of breast cancer. Breast Cancer [book online]. Available: https://doi.org/10.36255/exon-publications-breast-cancer-subtypes [22 Jun 2022]
Rosati, R., Oppat, K., Huang, Y., Kim, S. and Ratnam, M. 2020. Clinical association of progesterone receptor isoform A with breast cancer metastasis consistent with its unique mechanistic role in preclinical models. BMC cancer. 20: 1-10.
Sen, N., Gui, B. and Kumar, R. 2014. Role of MTA1 in cancer progression and metastasis. Cancer Metastasis Rev. 33: 879-889.
Sharaf, S.S., Jaganath Krishna, K.M. and Lekshmi, A. 2024. Subcellular expression of MTA1, HIF1A and p53 in primary tumour predicts aggressive triple negative breast cancers: a meta-analysis based study. J. Mol. Histol. 55, 303–315.
Sharma, G., Mirza, S., Parshad, R., Srivastava, A., Gupta, S.D., Pandya, P. and Ralhan, R. 2011. Clinical significance of Maspin promoter methylation and loss of its protein expression in invasive ductal breast carcinoma: correlation with VEGF-A and MTA1 expression. Tumour Biol. 32: 23-32.
Singh, R.R., Barnes, C.J., Talukder, A.H., Fuqua, S.A. and Kumar, R. 2005. Negative regulation of estrogen receptor alpha transactivation functions by LIM domain only 4 protein. Cancer Res. 65: 10594-10601.
Suvarna, K.S., Layton, C. and Bancroft, J.D. 2019. Bancroft's Theory and Practice of Histological Techniques. (8th Ed.). Amsterdam: Elsevier Health Sciences, Netherlands.
Tavasoly, A., Golshahi, H., Rezaie, A. and Farhadi, M. 2013. Classification and grading of canine malignant mammary tumors. Vet. Res. Forum.4: 25.
Vakkala, M., Pääkkö, P. and Soini, Y. 1999. Expression of caspases 3, 6 and 8 is increased in parallel with apoptosis and histological aggressiveness of the breast lesion. Br. J. Cancer. 81:592-599.
Wang, S., Li, Q., Wang, Y., Li, X., Wang, R., Kang, Y., Xue, X., Meng, R., Wei, Q. and Feng, X. 2018. Upregulation of circ-UBAP2 predicts poor prognosis and promotes triple-negative breast cancer progression through the miR-661/MTA1 pathway. Biochem. Biophys. Res. Commun. 505: 996-1002.
Zhao, L., Niu, F., Shen, H., Liu, X., Chen, L. and Niu, Y. 2016. Androgen receptor and metastasis-associated protein-1 are frequently expressed in estrogen receptor negative/HER2 positive breast cancer. Virchows Arch. 468: 687- 696.
© 2025 Jyothi et al. This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Jyothi K.B., Sajitha I.S., Prasanna K.S., Devi S.S., Divya C., Soumya Ramankutty. 2024. Characterisation of MTA1 Expression in Canine Mammary Neoplasms: A Comparative Study with Emphasis on Triple-Negative Phenotypes.
J. Vet. Anim. Sci. 56 (1):162-169